Hypercoagulation and complement: Connected players in tumor development and metastases

Gale, 2011, Continuing education course #2: current understanding of hemostasis, Toxicol. Pathol., 39, 273, 10.1177/0192623310389474 Renne, 2005, Defective thrombus formation in mice lacking coagulation factor XII, J. Exp. Med., 202, 271, 10.1084/jem.20050664 Loeffen, 2012, The impact of blood coagulability on atherosclerosis and cardiovascular disease, J. Thromb. Haemost.: JTH, 10, 1207, 10.1111/j.1538-7836.2012.04782.x Simmons, 2015, The coagulopathy of acute sepsis, Curr. Opin. Anaesthesiol., 28, 227, 10.1097/ACO.0000000000000163 Buller, 2007, Cancer and thrombosis: from molecular mechanisms to clinical presentations, J. Thromb. Haemost.: JTH, 5, 246, 10.1111/j.1538-7836.2007.02497.x Heit, 2000, Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study, Arch. Intern. Med., 160, 809, 10.1001/archinte.160.6.809 Khorana, 2008, Development and validation of a predictive model for chemotherapy-associated thrombosis, Blood, 111, 4902, 10.1182/blood-2007-10-116327 Khorana, 2007, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients, Cancer, 110, 2339, 10.1002/cncr.23062 Piccioli, 2004, Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial, J. Thromb. Haemost.: JTH, 2, 884, 10.1111/j.1538-7836.2004.00720.x Gil-Bernabe, 2013, Coagulation and metastasis: what does the experimental literature tell us?, Br. J. Haematol., 162, 433, 10.1111/bjh.12381 Nierodzik, 2006, Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype, Cancer Cell, 10, 355, 10.1016/j.ccr.2006.10.002 Palumbo, 2000, Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells, Blood, 96, 3302, 10.1182/blood.V96.10.3302 Andrianifahanana, 2001, Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance, Clin. Cancer Res., 7, 4033 Boccaccio, 2005, The MET oncogene drives a genetic programme linking cancer to haemostasis, Nature, 434, 396, 10.1038/nature03357 Darbousset, 2012, Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation, Blood, 120, 2133, 10.1182/blood-2012-06-437772 von Bruhl, 2012, Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo, J. Exp. Med., 209, 819, 10.1084/jem.20112322 Demers, 2012, Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis, Proc. Natl. Acad. Sci. U. S. A., 109, 13076, 10.1073/pnas.1200419109 Amara, 2008, Interaction between the coagulation and complement system, Adv. Exp. Med. Biol., 632, 71 Markiewski, 2007, Complement and coagulation: strangers or partners in crime?, Trends Immunol., 28, 184, 10.1016/j.it.2007.02.006 Bonavita, 2015, PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer, Cell, 160, 700, 10.1016/j.cell.2015.01.004 Guglietta, 2016, Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis, Nat. Commun., 7, 11037, 10.1038/ncomms11037 Markiewski, 2008, Modulation of the antitumor immune response by complement, Nat. Immunol., 9, 1225, 10.1038/ni.1655 Rutkowski, 2010, Cancer and the complement cascade, Mol. Cancer Res.: MCR, 8, 1453, 10.1158/1541-7786.MCR-10-0225 Surace, 2015, Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response, Immunity, 42, 767, 10.1016/j.immuni.2015.03.009 Dicke, 2015, Pathophysiology of trousseau's syndrome, Hamostaseologie, 35, 52, 10.5482/HAMO-14-08-0037 Aird, 2007, Vascular bed-specific thrombosis, J. Thromb. Haemost.: JTH, 5, 283, 10.1111/j.1538-7836.2007.02515.x Esmon, 2009, Basic mechanisms and pathogenesis of venous thrombosis, Blood Rev., 23, 225, 10.1016/j.blre.2009.07.002 Totan, 2001, Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia, Med. Pediatr. Oncol., 36, 429, 10.1002/mpo.1106 Herrmann, 2016, Vascular toxicities of cancer therapies: the old and the new – an evolving avenue, Circulation, 133, 1272, 10.1161/CIRCULATIONAHA.115.018347 Solari, 2016, High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy, Urol. Int., 96, 399, 10.1159/000445126 Posch, 2016, Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study (CATS), Clin. Cancer Res., 22, 200, 10.1158/1078-0432.CCR-14-3358 Onitilo, 2012, Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience, Thromb. Res., 130, 27, 10.1016/j.thromres.2011.11.025 Oberhoff, 2000, Adjuvant CMF-chemotherapy and haemostasis. Effect of classical and modified adjuvant CMF-chemotherapy on blood coagulation fibrinolysis in patients with breast cancer, Eur. J. Gynaecol. Oncol., 21, 147 Hisada, 2015, Venous thrombosis and cancer: from mouse models to clinical trials, J. Thromb. Haemost.: JTH, 13, 1372, 10.1111/jth.13009 Ay, 2009, D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study, J. Clin. Oncol., 27, 4124, 10.1200/JCO.2008.21.7752 Morrissey, 1987, Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade, Cell, 50, 129, 10.1016/0092-8674(87)90669-6 Bogdanov, 2003, Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein, Nat. Med., 9, 458, 10.1038/nm841 Censarek, 2007, Alternatively spliced human tissue factor (asHTF) is not pro-coagulant, Thromb. Haemost., 97, 11, 10.1160/TH06-09-0524 Bharthuar, 2013, Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers, Thromb. Res., 132, 180, 10.1016/j.thromres.2013.06.026 Thaler, 2014, Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia, Thromb. Res., 133, 303, 10.1016/j.thromres.2013.12.029 Thaler, 2013, Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients, Thromb. Res., 131, 162, 10.1016/j.thromres.2012.09.020 Cocco, 2011, Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor, BMC Cancer, 11, 263, 10.1186/1471-2407-11-263 Yu, 2004, Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells, J. Thromb. Haemost.: JTH, 2, 2065, 10.1111/j.1538-7836.2004.00972.x Rao, 2011, Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis, Int. J. Colorectal Dis., 26, 593, 10.1007/s00384-011-1164-1 D'Asti, 2016, Tissue factor regulation by miR-520g in primitive neuronal brain tumor cells: a possible link between oncomirs and the vascular tumor microenvironment, Am. J. Pathol., 186, 446, 10.1016/j.ajpath.2015.10.020 Yu, 2013, MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion, Mol. Cell. Biochem., 380, 239, 10.1007/s11010-013-1679-6 Bastarache, 2011, Interferon-gamma and tumor necrosis factor-alpha act synergistically to up-regulate tissue factor in alveolar epithelial cells, Exp. Lung Res., 37, 509, 10.3109/01902148.2011.605512 Wygrecka, 2012, TGF-beta1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner, Am. J. Respir. Cell Mol. Biol., 47, 614, 10.1165/rcmb.2012-0097OC Sun, 2013, Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor, Acta Oncol., 52, 842, 10.3109/0284186X.2013.705890 Davila, 2008, Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation, J. Thromb. Haemost.: JTH, 6, 1517, 10.1111/j.1538-7836.2008.02987.x Thomas, 2015, Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice, J. Thromb. Haemost.: JTH, 13, 1310, 10.1111/jth.13002 Thaler, 2012, Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients, J. Thromb. Haemost.: JTH, 10, 1363, 10.1111/j.1538-7836.2012.04754.x Thomas, 2009, Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo, J. Exp. Med., 206, 1913, 10.1084/jem.20082297 Aras, 2004, Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia, Blood, 103, 4545, 10.1182/blood-2003-03-0713 Shet, 2003, Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes, Blood, 102, 2678, 10.1182/blood-2003-03-0693 Pelaseyed, 2014, The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system, Immunol. Rev., 260, 8, 10.1111/imr.12182 Krishn, 2016, Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological implication(s) for early diagnosis of colon cancer, Cancer Lett., 374, 304, 10.1016/j.canlet.2016.02.016 Paszek, 2014, The cancer glycocalyx mechanically primes integrin-mediated growth and survival, Nature, 511, 319, 10.1038/nature13535 Wahrenbrock, 2003, Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas, J. Clin. Invest., 112, 853, 10.1172/JCI200318882 Shao, 2011, Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome, Blood, 118, 4015, 10.1182/blood-2011-07-368514 Blix, 2013, White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism – the Tromso study, PLoS One, 8, e73447, 10.1371/journal.pone.0073447 Go, 2015, Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism, Tumour Biol., 36, 7631, 10.1007/s13277-015-3475-2 Go, 2014, Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer, Lung Cancer, 84, 79, 10.1016/j.lungcan.2014.01.014 Egorina, 2008, Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer, Blood, 111, 1208, 10.1182/blood-2007-08-107698 Massberg, 2010, Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases, Nat. Med., 16, 887, 10.1038/nm.2184 Fuchs, 2007, Novel cell death program leads to neutrophil extracellular traps, J. Cell Biol., 176, 231, 10.1083/jcb.200606027 Yipp, 2012, Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo, Nat. Med., 18, 1386, 10.1038/nm.2847 Brill, 2012, Neutrophil extracellular traps promote deep vein thrombosis in mice, J. Thromb. Haemost.: JTH, 10, 136, 10.1111/j.1538-7836.2011.04544.x Fuchs, 2010, Extracellular DNA traps promote thrombosis, Proc. Natl. Acad. Sci. U. S. A., 107, 15880, 10.1073/pnas.1005743107 Fuchs, 2012, Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies, Blood, 120, 1157, 10.1182/blood-2012-02-412197 Amara, 2010, Molecular intercommunication between the complement and coagulation systems, J. Immunol., 185, 5628, 10.4049/jimmunol.0903678 Sims, 1988, Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity, J. Biol. Chem., 263, 18205, 10.1016/S0021-9258(19)81346-7 Polley, 1983, Human platelet activation by C3a and C3a des-arg, J. Exp. Med., 158, 603, 10.1084/jem.158.2.603 Kourtzelis, 2010, Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis, Blood, 116, 631, 10.1182/blood-2010-01-264051 Wojta, 2002, C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils, Blood, 100, 517, 10.1182/blood.V100.2.517 Laudes, 2002, Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis, Am. J. Pathol., 160, 1867, 10.1016/S0002-9440(10)61133-9 Redecha, 2007, Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury, Blood, 110, 2423, 10.1182/blood-2007-01-070631 Krigsfeld, 2013, Is disseminated intravascular coagulation the major cause of mortality from radiation at relatively low whole body doses?, Radiat. Res., 180, 231, 10.1667/RR3321.1 Han, 2006, Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma, J. Clin. Oncol., 24, 755, 10.1200/JCO.2005.02.9181 Masago, 2011, Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer, Med. Oncol., 28, 351, 10.1007/s12032-010-9454-y Nitori, 2005, Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma, Clin. Cancer Res., 11, 2531, 10.1158/1078-0432.CCR-04-0866 Harris, 2002, Hypoxia – a key regulatory factor in tumour growth, Nat. Rev. Cancer, 2, 38, 10.1038/nrc704 Nishi, 2004, Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT), Mol. Cell. Biol., 24, 6076, 10.1128/MCB.24.13.6076-6083.2004 Steinbrecher, 2010, Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen, Cancer Res., 70, 2634, 10.1158/0008-5472.CAN-09-3465 Turpin, 2014, Thrombin drives tumorigenesis in colitis-associated colon cancer, Cancer Res., 74, 3020, 10.1158/0008-5472.CAN-13-3276 Vossen, 2011, Clotting factor gene polymorphisms and colorectal cancer risk, J. Clin. Oncol., 29, 1722, 10.1200/JCO.2010.31.8873 Agostino, 1966, Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat, Cancer, 19, 284, 10.1002/1097-0142(196602)19:2<284::AID-CNCR2820190223>3.0.CO;2-0 Esumi, 1991, Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor, Cancer Res., 51, 4549 Coupland, 2012, Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells, Cancer Res., 72, 4662, 10.1158/0008-5472.CAN-11-4010 Hu, 2004, Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis, Blood, 104, 2746, 10.1182/blood-2004-03-1047 Villares, 2011, Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype, Proc. Natl. Acad. Sci. U. S. A., 108, 626, 10.1073/pnas.1006886108 Konstantopoulos, 1996, Effects of fluid dynamic forces on vascular cell adhesion, J. Clin. Invest., 98, 2661, 10.1172/JCI119088 Gay, 2011, Contribution of platelets to tumour metastasis, Nat. Rev. Cancer, 11, 123, 10.1038/nrc3004 Labelle, 2011, Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis, Cancer Cell, 20, 576, 10.1016/j.ccr.2011.09.009 Bobek, 2005, Anticoagulant drugs increase natural killer cell activity in lung cancer, Lung Cancer, 47, 215, 10.1016/j.lungcan.2004.06.012 Palumbo, 2005, Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells, Blood, 105, 178, 10.1182/blood-2004-06-2272 Gil-Bernabe, 2012, Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice, Blood, 119, 3164, 10.1182/blood-2011-08-376426 Cools-Lartigue, 2013, Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis, J. Clin. Invest., 10.1172/JCI67484 Algra, 2012, Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol., 13, 518, 10.1016/S1470-2045(12)70112-2 Chan, 2012, Aspirin in the chemoprevention of colorectal neoplasia: an overview, Cancer Prev. Res., 5, 164, 10.1158/1940-6207.CAPR-11-0391 Zacharski, 2005, Warfarin versus low-molecular-weight heparin therapy in cancer patients, Oncologist, 10, 72, 10.1634/theoncologist.10-1-72 Bell, 1985, Trousseau's syndrome. Devastating coagulopathy in the absence of heparin, Am. J. Med., 79, 423, 10.1016/0002-9343(85)90028-2 Meyer, 2002, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch. Intern. Med., 162, 1729, 10.1001/archinte.162.15.1729 Varki, 2007, Trousseau's syndrome: multiple definitions and multiple mechanisms, Blood, 110, 1723, 10.1182/blood-2006-10-053736 Akl, 2014, Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer, Cochrane Database Syst. Rev., 6, 10.1002/14651858.CD009447.pub2 Hillis, 2015, Acute phase treatment of VTE: anticoagulation, including non-vitamin K antagonist oral anticoagulants, Thromb. Haemost., 113, 1193, 10.1160/TH14-12-1036 Lee, 2003, N. Engl. J. Med., 349, 146, 10.1056/NEJMoa025313 Spirk, 2011, Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II, Thromb. Haemost., 105, 962, 10.1160/TH11-01-0002 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N. Engl. J. Med., 369, 799, 10.1056/NEJMoa1302507 Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N. Engl. J. Med., 366, 1287, 10.1056/NEJMoa1113572 Friedman, 2012, Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty, Am. Health Drug Benefits, 5, 115 Investigators, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N. Engl. J. Med., 363, 2499, 10.1056/NEJMoa1007903 Lyman, 2015, Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014, J. Clin. Oncol., 33, 654, 10.1200/JCO.2014.59.7351 Klerk, 2005, The effect of low molecular weight heparin on survival in patients with advanced malignancy, J. Clin. Oncol., 23, 2130, 10.1200/JCO.2005.03.134 Kuderer, 2007, A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications, Cancer, 110, 1149, 10.1002/cncr.22892 Gleeson, 2014, Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells, Haematologica, 99, 185, 10.3324/haematol.2013.086918 Hostettler, 2007, P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins, FASEB J., 21, 3562, 10.1096/fj.07-8450com Girardi, 2004, Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, Nat. Med., 10, 1222, 10.1038/nm1121